AsciminibMeSH Supplementary Concept

https://www.has-sante.fr/jcms/p_3407460/fr/scemblix-asciminib-leucemie-myeloide-chronique
2023
false
false
false
France
insurance, health, reimbursement
treatment outcome
asciminib
leukemia, myelogenous, chronic, bcr-abl positive
Chronic Myeloid Leukemia, Philadelphia Chromosome Positive, BCR-ABL1 Positive
recurrence
T315I mutation
Refractory Chronic Myeloid Leukemia, BCR-ABL1 Positive
Recurrent Chronic Myeloid Leukemia, BCR-ABL1 Positive
administration, oral
antineoplastic agents
evaluation of the transparency committee
leukemia, myelogenous, chronic, bcr-abl positive
asciminib

---
https://www.has-sante.fr/jcms/p_3427549/fr/scemblix-asciminib-leucemie-myeloide-chronique
2023
false
false
false
France
treatment outcome
insurance, health, reimbursement
adult
Chronic Myeloid Leukemia, Philadelphia Chromosome Positive, BCR-ABL1 Positive
Refractory Chronic Myeloid Leukemia, BCR-ABL1 Positive
administration, oral
Tyrosine Kinase Inhibitors
asciminib
evaluation of the transparency committee
leukemia, myelogenous, chronic, bcr-abl positive
asciminib

---
https://ansm.sante.fr/tableau-acces-derogatoire/scemblix-20-mg-40-mg-comprimes-pellicules
2023
false
false
false
France
French
asciminib
administration, oral
guidelines for drug use
asciminib
protein kinase inhibitors
summary of product characteristics
package leaflet
leukemia, lymphocytic, acute, L2
leukemia, lymphocytic, acute, L2
mutation
T315I mutation
leukemia, myelogenous, chronic, bcr-abl positive
leukemia, myelogenous, chronic, bcr-abl positive

---
https://www.has-sante.fr/jcms/p_3396012/fr/scemblix-asciminib-leucemie-myeloide-chronique
2022
false
false
false
France
French
evaluation of the transparency committee
insurance, health, reimbursement
treatment outcome
asciminib
asciminib
protein kinase inhibitors
leukemia, myelogenous, chronic, bcr-abl positive
adult
Philadelphia chromosome positive chronic myelogenous leukemia (disorder)
administration, oral

---
https://www.has-sante.fr/jcms/p_3391292/fr/scemblix-asciminib-lmc
2022
false
false
false
France
treatment outcome
insurance, health, reimbursement
asciminib
adult
Refractory Chronic Myeloid Leukemia, BCR-ABL1 Positive
guidelines for drug use
administration, oral
protein kinase inhibitors
antineoplastic agents
evaluation of the transparency committee
leukemia, myelogenous, chronic, bcr-abl positive
asciminib

---
https://www.has-sante.fr/jcms/p_3333278/fr/scemblix-asciminib-lmc
https://www.has-sante.fr/jcms/p_3333291/fr/decision-n-2022-0127/dc/sem-du-14-avril-2022-du-college-de-la-haute-autorite-de-sante-portant-autorisation-d-acces-precoce-de-la-specialite-scemblix
2022
false
false
false
France
evaluation of the transparency committee
asciminib
asciminib

---
https://www.cadth.ca/fr/asciminib
2022
false
false
false
Canada
French
canada
asciminib
drug evaluation
asciminib

---
https://www.ema.europa.eu/en/medicines/human/EPAR/scemblix
2022
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
asciminib
asciminib
orphan drug production
asciminib
antineoplastic agents
antineoplastic agents
leukemia, myelogenous, chronic, bcr-abl positive
Refractory Chronic Myeloid Leukemia, BCR-ABL1 Positive
administration, oral
Tyrosine Kinase Inhibitor
protein kinase inhibitors
protein kinase inhibitors
protein-tyrosine kinases
product surveillance, postmarketing
asciminib hydrochloride
asciminib hydrochloride
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
Tyrosine Kinase Inhibitors

---